Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This case report describes a rare instance of renal cell carcinoma metastasizing to the ovary and early onset of alopecia after beginning sunitinib treatment, though hypothyroidism and dandruff complicate attribution to the drug.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

This case series found that paclitaxel and nab-paclitaxel may be safe and effective chemotherapy options for hemodialysis patients with unresectable advanced or recurrent gastric cancer.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

This review discusses recent developments in targeted melanoma therapies, including BRAF/MEK/ERK pathway inhibitors and challenges like resistance and skin toxicities, but reports no new clinical results.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This review summarizes the antioxidant and anticarcinogenic properties of Indian Gooseberry, its phytochemical composition, and its use in traditional Ayurvedic medicine, but reports no new clinical results.

In this review, the researchers compared the traditional use of Senna Makki in Unani medicine for various ailments to modern pharmacological evidence, endorsing its role as a laxative but indicating further research is needed for its efficacy in other therapeutic areas.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

A man developed alopecia areata after starting cancer treatment with vandetanib.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.